Loader

Pathways

PathWhiz ID Pathway Meta Data

PW176144

Pw176144 View Pathway
metabolic

Telaprevir Predicted Metabolism Pathway new

Homo sapiens
Metabolites of Telaprevir are predicted with biotransformer.

PW127448

Pw127448 View Pathway
drug action

Telavancin Action Pathway

Staphylococcus aureus
Telavancin is an antibacterial agent used in the treatment of complicated skin and skin structure infections and types of hospital-acquired bacterial pneumonia. Telavancin is a semi-synthetic derivative of vanocymycin that has bactericidal activity against Methicillin-resistant Staphylococcus aureus (MRSA) and other gram-positive bacteria. It is used for the treatment of complicated skin and skin structure infections (cSSSI) caused by gram-positive bacteria like methicillin-susceptible or -resistant Staphylococcus aureus, vancomycin-susceptible Enterococcus faecalis, and Streptococcus pyogenes, Streptococcus agalactiae, or Streptococcus anginosus group. It is also used for the treatment of adult patients with hospital-acquired bacterial pneumonia (HAP) and ventilator-associated bacterial pneumonia (VAP), known or suspected to be caused by susceptible isolates of Staphylococcus aureus (including methicillin-susceptible and methicillin-resistant S. aureus). Telavancin prevents polymerization of N-acetylmuramic acid (NAM) and N-acetylglucosamine (NAG) and cross-linking of peptidoglycan by binding to D-Ala-D-Ala. As a result, inhibition of bacterial cell wall synthesis occurs. Furthermore, telavancin disrupts membrane potential and cell permeability as a result of the lipophillic side chain moiety. This additional bactericidal mechanism is what sets telavancin apart from vancomycin.

PW145707

Pw145707 View Pathway
drug action

Telavancin Drug Metabolism Action Pathway

Homo sapiens

PW127466

Pw127466 View Pathway
drug action

Telbivudine Action Pathway

Homo sapiens
Telbivudine is a synthetic thymidine nucleoside analog with specific activity against the hepatitis B virus. It is administered orally. Telbivudine is the unmodified β–L enantiomer of the naturally occurring nucleoside, thymidine. It undergoes phosphorylation via interaction with cellular kinases to form the active metabolite, telbivudine 5'-triphosphate. Telbivudine 5'–triphosphate inhibits HBV DNA polymerase (reverse transcriptase) by competing with the natural substrate, thymidine 5'–triphosphate. This leads to the chain termination of DNA synthesis, thereby inhibiting viral replication. Incorporation of telbivudine 5'–triphosphate into viral DNA also causes DNA chain termination, resulting in inhibition of HBV replication. Telbivudine inhibits anticompliment or second-strand DNA. This causes DNA chain termination, preventing the growth of viral DNA. Less Viral DNA is transported into the nucleus, therefore, less viral DNA is integrated into the host DNA. Less viral proteins produced, fewer viruses can form.

PW132383

Pw132383 View Pathway
metabolic

Telbivudine Drug Metabolism

Homo sapiens
Telbivudine is a drug that is not metabolized by the human body as determined by current research and biotransformer analysis. Telbivudine passes through the liver and is then excreted from the body mainly through the kidney.

PW145348

Pw145348 View Pathway
drug action

Telbivudine Drug Metabolism Action Pathway

Homo sapiens

PW000350

Pw000350 View Pathway
drug action

Telithromycin Action Pathway

Homo sapiens
Telithromycin is a semi-synthetic erythromycin derivative. It belongs to the chemical family called ketolides, a group belonging to the macrolide-lincosamide-streptogramin (MLS) class. Telithromycin prevents bacterial growth by inhibiting bacterial protein synthesis. Similar to macrolides, telithromycin directly blocks translation of the bacterial 23S ribosomal RNA; however, unlike macrolides, telithromycin also blocks bacterial ribosomal assembly (mechanism not shown). Telithromycin binds to two sites on the 50S ribosomal subunit, domains II and V of the 23S rRNA, whereas macrolides bind only to domain V. The C11-12 carbamate side chain is thought to contribute to a higher binding affinity of telithromycin compared to erythromycin A. In erythromycin A-susceptible bacteria, telithromycin exhibits 10 times greater affinity than erythromycin. Its relative binding affinity is further increased to 25 times greater in macrolide-resistant bacteria strains. This is likely due to the additional binding site on domain II since macrolide resistance occurs as a result of alterations in the domain V binding site.

PW128355

Pw128355 View Pathway
drug action

Telithromycin Action Pathway

Homo sapiens
Telithromycin is an oral antibiotic drug that is a semi-synthetic erythromycin derivative. Telithromycin is metabolized in the liver by cytochrome P450 and 3A4 enzymes. Telithromycin penetrates the bacterial cell wall and acts on the ribosomal subunits to interfere with protein synthesis. These compounds act by binding to the 50S subunit of the 70S ribosomal subunit this in turn blocks protein elongation of the bacterial ribosome. Telithromycin binds to domains II and V of the 23S RNA of the 50S subunit of the ribosome. As a result, protein synthesis is inhibited, preventing bacterial growth and this may even kill the bacteria. Common side effects from taking Telithromycin include dizziness, headache, and taste disturbances, with the chance of experiencing more adverse effects such as diarrhea, nausea, vomiting, loose stools, abdominal pain, flatulence and dyspepsia.

PW145074

Pw145074 View Pathway
drug action

Telithromycin Drug Metabolism Action Pathway

Homo sapiens

PW176510

Pw176510 View Pathway
metabolic

Telithromycin Predicted Metabolism Pathway

Homo sapiens
Metabolites of Telithromycin are predicted with biotransformer.